Multiple Sclerosis (MS) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Multiple Sclerosis Emerging Therapy and TPP Insights

Thelansis’s “Multiple Sclerosis (MS) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Multiple Sclerosis Overview

Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system, where inflammation damages myelin, axons and neurons. Its course may be relapsing-remitting or progressive. Symptoms vary and include optic neuritis, numbness, weakness, spasticity, balance problems, fatigue and cognitive changes. Disease-modifying therapies (DMTs), from injectables and oral agents to monoclonal antibodies, reduce relapses and inflammatory activity; some slow disability progression. However, progression may persist despite relapse control, and established neurological damage may be irreversible. Research targets Bruton tyrosine kinase (BTK), neuroprotection and remyelination. Tolebrutinib (Cenrifki) received EU authorisation in June 2026 for adults with secondary progressive MS without relapses for two years. Remibrutinib reported positive Phase III results in relapsing MS in October 2026 but is not yet approved for MS. Restoring damaged neural tissue remains a major unmet need.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)